

Genomtec S.A. expands its Genomtec ID platform to oncology and has filed a patent application specific to oncology diagnostics

Genomtec S.A., a leading molecular diagnostic company based in Wroclaw, Poland, has successfully completed an expansion of its Genomtec ID platform to the field of oncology diagnostics leading to its submission of a patent protection application for a novel oncologic diagnostic method that it developed. This method involves isothermal amplification of nucleic acids for the detection of genetic variants applicable for oncology diagnostics.

The application submitted to the Polish Patent Office for the granting of a patent for an invention in the field of oncological diagnostics is the 37th patent application of the company Genomtec. The company's patent strategy includes extending protection for this invention through the international PCT procedure.

"We are very pleased that the fast pace of work by the entire Genomtec team has allowed us to transition from the ideation stage to the formulation of a patent application and achieve an important milestone in just a few months. Now, we are not far from the Proof-of-Concept stage. I believe that the potential scope of implementing our technology is not limited to the areas of upper respiratory tract disease diagnostics or oncology, which are already some of the most attractive segments of the diagnostics market. Furthermore, the technology we are developing may be utilized in drug development, companion diagnostics, drug dosing, virus variant identification, drug-resistant bacterial strain research, as well as in veterinary medicine and the food industry." **said Dr Miron Tokarski, co-author of the filed patent, President, Co-founder, and a principle shareholder of Genomtec S.A.**

The development of the oncology project was one of the objectives of the equity offerings Series M and N conducted in April of this year, from which Genomtec raised gross PLN 13.1 million. Between May and August of this year, the company conducted laboratory experiments on the application of a method in the diagnosis of one of the most common cancers. During this period, through the analysis of various possible isothermal amplification mechanisms and hundreds of tests, a method was created that enables precise detection of a range of genetic variants specific to Oncology markers.

Genomtec's expansion of its ID platform to the field of oncology diagnostics and submission of its patent protection application for a novel oncologic diagnostic method demonstrates the versatility of its Genomtec ID platform in two otherwise distinct markets – infectious disease and oncology. This versatility, itself, may significantly expand the breadth of potential interest for Genomtec and its technology platform

According to a report by Market and Markets, the global cancer diagnostics market was valued at USD 17.2 billion in 2021. Experts from this company estimate that the average annual growth rate of this market in the coming years will be 11.5%, reaching a value of USD 26.6 billion in 2026. Therapeutic companies are increasingly focused on precision medicine which targets individual variants (genetic

mutations) and their respective pathways making precise molecular diagnostics vital to drug development and use in this USD 17.2 billion market.

Genomtec's innovative solutions using isothermal amplification are being systematically secured by expansion of the patent cloud. Intellectual property is a product and a competitive advantage, while development of the patent cloud has a major impact on the Company's value. The size and proper protection of the cloud are key to the market position. Genomtec solutions are protected as of patent submission with the relevant authority. Genomtec already holds a total of 10 patents and has 27 patent pending applications.

"Filing a patent application in the field of oncology expands the scope of applications for our proprietary SNAAT/LAMP method beyond infectious disease diagnostics, opening the door for discussions with a much broader range of potential M&A partners. At the same time, we continue to work on our most advanced project related to the diagnosis of respiratory infectious diseases. We are collaborating with experienced CDMO partners to optimize costs in the area of reaction card and analyzer. In the coming months, with the start of the respiratory illness season, we will resume the clinical trials that were initiated. The processes leading us towards commercialization are running in parallel with certification process so that, as planned, we may maintain the continuity of our existing marketing authorization, registering products in accordance with incoming IVDR guidelines by the end of May 2025." **said Dr Miron Tokarski.**

About Genomtec

Genomtec is a MedTech company specializing in the development of advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for fast and precise molecular analysis outside the laboratory environment without the need to involve qualified laboratory personnel. The solution uses microfluidic technology and proprietary patented SNAAT isothermal technology. The Genomtec technology is protected by 10 patents m.in in Europe, the USA and Japan, and over 37 patent applications on global markets.

The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections.

The company's registered office is located in Wrocław. Genomtec also has a branch in the UK, where part of the international research and engineering team is located.

More information is available on the shelf page: www.genomtec.com

Media Contact:

Michał Wierzchowski

Tel.: +48 531 613 067

michal.wierzchowski@ccgroup.pl

Contact for investors:

Agata Dzieciolowska

Tel.: +48 606 205 119

agata.dzieciolowska@ccgroup.pl

Małgorzata Młynarska

Tel.: +48 697 613 709

malgorzata.mlynarska@ccgroup.pl

By gaining access to press releases ("Press Releases") of Genomtec S.A. with its registered office in Wrocław ("Company") and reading their content, you acknowledge and agree to be bound by the following reservations and conditions: The Company's Press Releases are for promotional and informational purposes only and should under no circumstances constitute the basis for making a decision to purchase the Company's shares. The Press Releases have been prepared by the Company for informational purposes only, and none of the provisions contained therein constitutes any recommendation regarding the purchase of shares, does not constitute an offer to sell the Company's securities or information on the terms of their acquisition or subscription constituting a sufficient basis for making a decision to purchase or subscribe for these securities, and none of the provisions contained therein constitutes investment advice, legal or tax, nor is it an indication that any investment or strategy is appropriate to the individual circumstances of the investor. Investing in the Company's securities is associated with high risk inherent in equity capital market instruments and risks related to the Company's operations and the environment in which the Company operates. All rights to the Press Releases and to their individual elements, including proprietary copyrights, are vested in the Company. In addition, the Company indicates that the reproduction, distribution, transmission or making available of the Press Releases may be subject to legal restrictions (restrictions and their scope may vary from jurisdiction to jurisdiction) and any person to whom the Press Releases are provided or otherwise made available should familiarize themselves with such restrictions and strictly comply with them. The Press Releases, or any part thereof, may not be distributed in the United States of America, Canada, Australia or Japan or to U.S. Persons. Persons reviewing the Press Releases also represent that they are not covered by the applicable laws of any jurisdiction in which the display, distribution or publication of materials contained in the Press Releases would be prohibited or would require appropriate permission or permission. The Press Releases are for informational purposes only and do not constitute an offer to sell securities or an offer to obtain an offer to buy securities or any other instruments or shares in the Company or any other undertaking. The Press Releases also do not constitute an offer to cooperate on any other terms, or an offer to sell or an invitation to submit offers to buy, or subscriptions for shares of the Company or any other securities of either the Company or third parties. The content of the Press Releases does not constitute, and will not be incorporated by reference, any agreement between the Company and any third party, nor shall it give rise to any obligations of the Company, persons acting on behalf of the Company or persons to whom it is made available. Persons to whom the Press Releases are made available should not rely on them in connection with any contract, obligation, or intention of any other action relating to the Company. The Press Releases do not contain a complete or complete financial or commercial analysis of the Company. The Press Releases do not represent a complete or comprehensive analysis of the Company's position or prospects. Press releases have been prepared with due diligence and attention to the quality of information contained therein, however, there is a risk of inaccuracies as well as omission of some information. Any decisions concerning the Company should be made on the basis of independently conducted analyses and research. Persons who have read the Press Releases bear full responsibility for their possible assessment of the Company's situation and forecasts of its future development. In the event that the Press Releases contain forward-looking content or statements, including analyses regarding the possible or expected future financial or commercial results of the Company, each such statement or content is subject to risk. The risk referred to in the preceding sentence consists of both factors known and unknown to the Company. Due to the possibility of a significant number of unforeseen events and other factors that may cause the actual financial results of the Company as well as the situation in the industry in which the Company operates, to the extent that they contain statements regarding the future. Nothing in the Press Releases should be construed as a guarantee or assurance or commitment that the Company will achieve any particular financial or commercial performance in the future. The Company, its members of its bodies and directors, as well as shareholders, advisors or representatives of the Company make no express or implied representations, warranties or warranties as to the accuracy, completeness, correctness of the information and content contained in the Press Releases, or that in no event can any such content or information mislead the recipient. The Press Releases and the content contained therein have not been verified

by entities independent of the Company. To the fullest extent permitted by law, the liability of the persons indicated above for any statements, content or statements contained in the Press Releases is excluded, including for any damage that could be caused by compliance with these statements, content or statements by persons to whom the Press Releases have been made available. No statement contained in the Press Releases results in any of the indicated entities incurring any obligation. The Company, members of its bodies and management as well as shareholders, advisors, representatives of the Company are exempt from liability for any consequences of the use of information, data or statements contained in the Press Release, or any part thereof, regardless of the manner and purpose of such use. All responsibility for the use of any information contained in the Press Releases rests with the person using such information. Any information, statement or analysis regarding the future may be changed by the Company or their representatives at any time without prior notice of such change. The Company, members of its bodies and management as well as shareholders, advisors, representatives of the Company are not obliged to update the Press Releases in the event of any changes or to provide the recipients of the Press Releases with any additional information. Nothing contained herein or in the Press Releases constitutes any recommendation regarding the purchase of shares or any other action having equivalent effects on the Company's shares or any other securities. None of the presented information constitutes forecasts, including but not limited to financial forecasts, and should not be interpreted as forecasts. This document or the Press Releases have not been approved or verified in any way by the Polish Financial Supervision Authority, and their content has not been audited or approved by the Warsaw Stock Exchange. Investment in shares involves a number of investment risks, therefore investors should carefully and thoroughly familiarize themselves with the risk associated with the Company's operations and the environment, in which the Company operates.